Follow sourced scientific, clinical, partnership, capacity, and financial developments. Factual summaries and business interpretations are presented separately.
Research runs each weekday at 8 a.m. Eastern Time. Channels update when qualifying developments are found. Editorial standards · RSS ↗
Viking announced the SUNRISE Phase 3 program for oral VK2735, a dual GLP-1/GIP agonist. Two placebo-controlled, 68-week studies each target 560 adults, with and without type 2 diabetes. This is an adjacent oral peptide delivery program rather than a confirmed cyclic peptide platform, and the announcement provides a trial start rather than Phase 3 efficacy results.
BioNTech reported that AHEAD-MERIT, a Phase 2/3 trial of BNT113 plus pembrolizumab, did not meet its progression-free survival dual primary endpoint versus pembrolizumab alone. The study enrolled patients with previously untreated, unresectable recurrent or metastatic HPV16-positive, PD-L1-expressing head and neck cancer. Overall-survival follow-up continues; under the prespecified design, a significant survival benefit could still establish a positive trial outcome.
Entera reported a post hoc analysis of its Phase 2 EB613 study and outlined a planned Phase 3 trial. Women with lower baseline bone density showed larger gains, but the relevant subgroups were small. EB613 is an oral PTH(1-34) delivery program, an adjacent noncyclic peptide approach; these exploratory findings do not establish fracture reduction.
Insilico Medicine nominated ISM9546 as a preclinical candidate for autoimmune diseases, including inflammatory bowel disease and rheumatoid arthritis. The company described an orally available, peripherally restricted VAV1 molecular glue degrader, reporting cellular degradation activity and anti-inflammatory effects in disease models. Its limited brain exposure is a design feature; human safety and efficacy have not been established.
Electron diffraction established the previously unresolved structure of buspirone hydrochloride Form 2. The study also prepared 15 multicomponent solids, including cocrystals, an ionic cocrystal, and salts, and compared conformations and thermal behavior. This expands structural knowledge of a long-marketed drug and provides a solid-form exploration example without demonstrating improved clinical performance for the newly prepared materials.
Lonza expanded its accelerated DNA-to-IND offering to bispecific antibodies, Fc-fusion proteins, and high-concentration drug product formulations. The program coordinates drug substance and drug product development and manufacturing. Lonza states that eligible programs can deliver toxicology drug substance in as little as three months and reach IND readiness in six months; these are supplier-reported timelines.
This repeat-dosing study examined whether changes in PEG chemistry, PEG concentration, RNA cargo, or administration route could overcome efficacy loss after an immunogenic nanoparticle dose. None reliably restored delivery in the tested setting, and reduced activity tracked anti-PEG antibodies. The results emphasize the interaction between ionizable lipids and innate immunity, without establishing that every PEG-containing product will behave identically.
Researchers combined a 520-member degradable lipid library with interpretable machine learning and a 10,920-member virtual design space. Independent mouse experiments identified PA97MD101 as a lead for hepatic mRNA expression, Cre-mediated recombination, and Cas9-based TTR suppression. The study links screening predictions with functional animal validation, without establishing clinical safety or efficacy.
Molecular dynamics simulations examined tecovirimat across solvent and concentration conditions. Molecular conformations changed relatively little, while intermolecular association patterns differed substantially between benzene and ethyl acetate. Those associations resembled packing motifs in known anhydrous polymorphs IV and VI. The study offers a mechanistic computational explanation; it does not establish prospective experimental prediction of polymorph outcomes.
Amphista announced the first patient dose in BRAMLIE, a Phase 1 study of AMX-883 in acute myeloid leukemia and high-risk myelodysplastic syndrome. The oral candidate recruits DCAF16 to degrade BRD9. The study will evaluate safety, pharmacokinetics, and preliminary activity, moving a non-cereblon, non-VHL degradation approach beyond preclinical models and into patients.
Catalent and Mantra have signed a commercial supply agreement covering single-serve over-the-counter oral gels. Catalent will provide formulation development, manufacturing, and packaging at its St. Petersburg, Florida, facility for products addressing occasional sleeplessness, pain, and menstrual discomfort. The announcement establishes a development and supply relationship; it does not report new clinical efficacy data or regulatory approvals for the portfolio.
RinuaGene announced an October 4 collaboration framework with the Medicines Patent Pool to explore development, potential licensing, technology transfer, and local manufacturing of investigational therapeutic mRNA candidate RG002 in selected low- and middle-income countries. Other mRNA candidates may also be assessed. This is an exploratory framework, not a completed license, completed technology transfer, or WHO endorsement of an approved product.
Explore company filters, side-by-side comparisons, private bookmarks, and member discussions.
